KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bionano Genomics (BNGO) Asset Writedowns and Impairment (2017 - 2024)

Historic Asset Writedowns and Impairment for Bionano Genomics (BNGO) over the last 6 years, with Q3 2024 value amounting to $7.2 million.

  • Bionano Genomics' Asset Writedowns and Impairment changed N/A to $7.2 million in Q3 2024 from the same period last year, while for Dec 2024 it was $7.6 million, marking a year-over-year change of. This contributed to the annual value of $7.2 million for FY2024, which is N/A changed from last year.
  • Bionano Genomics' Asset Writedowns and Impairment amounted to $7.2 million in Q3 2024.
  • Bionano Genomics' Asset Writedowns and Impairment's 5-year high stood at $7.2 million during Q3 2024, with a 5-year trough of $44000.0 in Q3 2020.
  • Moreover, its 3-year median value for Asset Writedowns and Impairment was $475000.0 (2020), whereas its average is $1.4 million.
  • Examining YoY changes over the last 5 years, Bionano Genomics' Asset Writedowns and Impairment showed a top increase of 1439.39% in 2020 and a maximum decrease of 1439.39% in 2020.
  • Bionano Genomics' Asset Writedowns and Impairment (Quarter) stood at $475000.0 in 2020, then increased by 29.68% to $616000.0 in 2022, then skyrocketed by 1068.83% to $7.2 million in 2024.
  • Its Asset Writedowns and Impairment was $7.2 million in Q3 2024, compared to $448000.0 in Q1 2024 and $616000.0 in Q4 2022.